

Hany A. Omar, Ph.D

Department of Pharmacology & Pharmacotherapeutics
College of Pharmacy, University of Sharjah,
United Arab Emirates
Office (+971) 65057411
hanyomar@sharjah.ac.ae
https://www.researchgate.net/profile/Hany_Omar/

PERSONAL DATA

- o Place of Birth: Cairo, Egypt
- o Nationality: Egyptian

ACADEMIC EDUCATION

- 2011-2012** **Postdoctoral fellow, Ohio State University, Comprehensive Cancer Center, USA**
Project: TRAIL/OSU-A9 pre-clinical studies and target validation for the treatment of liver cancer.
- 2006 - 2010** **Ph.D, The Ohio State University, OSBP, College of Pharmacy, USA**
Philosophy doctor degree in Molecular Pharmacology. Title of the thesis: "Molecular Pharmacology and Preclinical Studies of Novel Small-Molecule Targeted agents for the Treatment of Hepatocellular Carcinoma".
- Sep. 2009** **Foreign Pharmacy Graduate Equivalency Certificate, FPGEC, USA**
The FPGEC Certification Program evaluates the qualifications of foreign pharmacy graduates in accordance with USA standards for pharmacy education.
- 2000 – 2005** **M. Sc., Cairo University, Faculty of Pharmacy, Egypt**
Master degree of pharmaceutical sciences, Pharmacology and Toxicology. Title of the thesis: "Pharmacological study of the possible interactions between certain analgesics and some antioxidants in experimental animals".
- 1992 – 1998** **B.Sc., Cairo University, Faculty of Pharmacy, Egypt**
Bachelor degree of Pharmaceutical Sciences with a general grade of "Excellent" With Honors (GPA 4.0/4.0).

PROFESSIONAL EXPERIENCE

- 2017 - Current** *Associate professor of pharmacology, College of Pharmacy, University of Sharjah (UOS), UAE*
- 2013 - 2017** *Assistant professor of pharmacology, College of Pharmacy, University of Sharjah (UOS), UAE*
- 2016-Current** *Associate professor of pharmacology and molecular therapeutics, Faculty of Pharmacy, Beni-Suef*
(on leave) University (BSU), Egypt
- 2012 - 2013** *Assistant professor of pharmacology and molecular therapeutics, College of Pharmacy, Taif*
University (TU), KSA
- 2010 - 2012** *Assistant professor of pharmacology and molecular therapeutics, Faculty of Pharmacy, Beni-Suef*

- University (BSU), **Egypt**.
- 2010 - 2011 Postdoctoral fellow, The Ohio State University, College of Pharmacy & The Ohio State Medical Center (OSUMC), Columbus, OH, **USA**.
- 2006 - 2010 Teaching Assistant and Graduate Research Associate, College of Pharmacy, Ohio State Biochemistry Program (OSBP), The Ohio State University (OSU), Columbus, OH, **USA**.
- 2005 - 2006 Assistant lecturer and graduate research associate at the department of pharmacology and toxicology at Cairo University, Faculty of Pharmacy, Beni-Suef campus, **Egypt**.
- 1999 - 2005 Graduate research associate and instructor of Pharmacology & Toxicology at the Faculty of Pharmacy, Cairo University, Beni-Suef campus, **Egypt**.
- 1998 - 1999 Clinical pharmacist at the National Cancer Institute working in the preparation of intravenous admixtures of cancer chemotherapeutic agents, Cairo, **Egypt**

PUBLICATIONS

I. RESEARCH PUBLICATIONS

- 1- Mai F. Tolba, Ahmed T. El-Serafi, **Hany A. Omar**. Caffeic acid phenethyl ester protects against glucocorticoid-induced osteoporosis *in vivo*: Impact on oxidative stress and RANKL/OPG signals. [*Toxicology and Applied Pharmacology*](#), June 2017 324: 26-35 [Link](#)
- 2- Khaled R. A. Abdellatif, Eman K. A. Abdelall, Mohamed A. Abdelgawad, Dina M. E. Amin, **Hany A. Omar**. Design, synthesis and biological evaluation of new 4-(4-substituted-anilino)quinoline derivatives as anticancer agents. [*Medicinal Chemistry Research*](#), May 2017 26 (5): 929-939 [Link](#)
- 3- Ahmed H. Abdelazeema, Mohammed T. El-Saadi, Asmaa G. Safi El-Din, **Hany A. Omar** and Samir M. El-Moghazy. Design, Synthesis and Analgesic/Anti-inflammatory Evaluation of Novel Diarylthiazole and Diarylimidazole Derivatives Towards Selective COX-1 Inhibitors with Better Gastric Profile. [*Bioorganic & Medicinal Chemistry*](#) 2017 Jan 15;25(2):665-676. [Link](#)
- 4- **Hany A. Omar**, Mai F. Tolba, Jui-Hsiang Hung, Taleb H. AlTel. OSU-2S/sorafenib synergistic antitumor combination against hepatocellular carcinoma: The role of PKC δ /p53. [*Frontiers in Pharmacology*](#) 2016 Nov 30;7:463 [Link](#)
- 5- Jui-Hsiang Hung, Chia-Yun Chen, **Hany A. Omar**, Kuo-Yuan Huang, Che-Chia Tsao, Chien-Chih, Chiu, Yi-Ling Chen, Po-Han Chen, Yen-Ni Teng. Reactive oxygen species mediate terbufos-induced apoptosis in mouse testicular cell lines via the modulation of cell cycle and pro-apoptotic proteins. [*Environmental Toxicology*](#), December 2016, 31(12):1888-98 [Link](#)
- 6- Mai F. Tolba, **Hany A. Omar**, Samar S. Azab, Amani E. Khalifa, Ashraf B. Abdel-Naim, Sherif Z. Abdel-Rahman. Caffeic acid phenethyl ester: A review of its antioxidant, antimicrobial activities, protective effects against ischemia reperfusion injury and drug adverse reactions. [*Critical Reviews in Food Science and Nutrition*](#), 2016 Oct 2;56(13):2183-90. [Link](#)
- 7- Ahmed Abdelazeem, Yasser Mohamed, Ahmed Gouda, **Hany Omar**, Majed Al Robaian. Novel Thymohydroquinone Derivatives as Potential Anticancer Agents: Design, Synthesis and Biological

- Screening. *Australian Journal of Chemistry*, June, 2016, 69, 1277–1284 [Link](#)
- 8- **Hany A. Omar**, Wafaa R. Mohamed, Hany H. Arab, El-Shaimaa A. Arafa. Tangeretin alleviates cisplatin-induced acute hepatic injury in rats: Targeting MAPKs and apoptosis. *PLoS ONE*, 2016 Mar 31;11(3):e0151649 [Link](#)
 - 9- Khaled R. Abdellatif, Phoebe F. Lamie, **Hany A. Omar**. 3-Methyl-2-phenyl-1-substituted-indole derivatives as indomethacin analogs: design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 2016 Apr;31(2):318-24. [Link](#)
 - 10- **Hany A. Omar**, Wafaa R. Mohamed, El-Shaimaa A. Arafa, Basim A. Shehata, Gamal A. El Sherbiny, Hany H. Arab, Abdel Nasser. A. M. Elgendy. Hesperidin alleviates cisplatin-induced hepatotoxicity in rats without inhibiting its antitumor activity. *Pharmacological Reports*, 2015. Sep;68(2): 349–56 [Link](#)
 - 11- Samir A. Salama, Mohammad S. Al-Harbi, Mohamed S. Abdel-Bakky, **Hany A. Omar**. Glutamyl cysteine dipeptide suppresses ferritin expression and alleviates liver injury in iron-overload rat model. *Biochimie*, June 2015. 115, 203-211. [Link](#)
 - 12- Kuan-Han Lee*, **Hany A. Omar***, Shu-Jing Wu, Pin-Shern Chen, Yu-Chung Chen, Yen-Ni Teng, Hung-Chang Huang, Clay C. C. Wang and Jui-Hsiang Hung. The effect of reactive oxygen species produced by 6-shogaol on cell cycle progression and cell death-associated signaling pathways in human hepatoma cells. *European Journal of Pharmacology*, June 2015, 762(5) 449–458. [Link](#) (*Equal contribution)
 - 13- Hany H. Arab, Samir A. Salama, **Hany A. Omar**, El-Shaimaa A. Arafa and Ibrahim A. Maghrabi. Diosmin protects against ethanol-induced gastric injury in rats: Novel anti-ulcer actions. *PLoS ONE*, March, 2015, 30;10(3):e0122417. [Link](#)
 - 14- Ahmed H. Abdelazeem, Ahmed M. Gouda, **Hany A. Omar**, Mai F. Tolba. Design, Synthesis and Biological Evaluation of Novel Diphenylthiazole-Based Cyclooxygenase Inhibitors as Potential Anticancer Agents. *Bioorganic Chemistry*, Dec 2014, 57, 132–141. [Link](#)
 - 15- **Hany A. Omar**, Mai F. Tolba and Maha M. Saber-Ayad. Potential Targets of Energy Restriction Mimetic Agents in Cancer Cells. *Future Oncology*, 2014 Dec;10(16): 2547-2550. [Link](#)
 - 16- Khaled R. A. Abdellatif, Heba A. H. Elshemy, Samir A. Salama, and **Hany A. Omar**. Synthesis, characterization and biological evaluation of novel 4'-fluoro-2'-hydroxy-chalcone derivatives as antioxidant, anti-inflammatory and analgesic agents. *Journal of Enzyme Inhibition and Medicinal Chemistry*, June 2015; 30(3):484-91. [Link](#)
 - 17- Ahmed H. Abdelazeem, Shaimaa A. Abdelatef, Mohammed T. El-Saadi, **Hany A. Omar**, Shabana I. Khan, Christopher R. McCurdy and Samir M. El-Moghazy. Novel Pyrazolopyrimidine Derivatives Targeting COXs and iNOS enzymes; Design, Synthesis and Biological Evaluation as Potential Anti-inflammatory Agents. *European Journal of Pharmaceutical Sciences*, Oct 2014, 62, 197–211. [Link](#)
 - 18- Hany H. Arab, Samir A. Salama, Ahmed H. Eid, **Hany A. Omar**, El-Shaimaa A. Arafa and Ibrahim A. Maghrabi. Camel's milk ameliorates TNBS-induced colitis in rats via down-regulation of

- inflammatory cytokines and oxidative stress. *Food and Chemical Toxicology*, April, **2014**, 69C:294-302. [Link](#)
- 19- Hany A. Omar, El-Shaimaa A. Arafa, A. Maghrabi and Jing-Ru Weng. Sensitization of Hepatocellular Carcinoma Cells to Apo2L/TRAIL by a Novel Akt/NF- κ B Signaling Inhibitor. *Basic & Clinical Pharmacology & Toxicology*, **2014 Jun**;114(6):464-71. [Link](#)
 - 20- Kuan-Han Lee, Wen-Yueh Ho, Shu-Jing Wu, Hany A. Omar, Po-Jui Huang, Clay C. C. Wang and Jui-Hsiang Hung. Modulation of cyclins, p53 and MAPK signaling in breast cancer cell lines by 4-(3,4,5-trimethoxyphenoxy)benzoic acid. *International Journal of Molecular Sciences*, **2014**, 15(1), 743-757. [Link](#)
 - 21- Samir A. Salama, Hany A. Omar, Ibrahim A. Maghrabi, Mohammed S. AlSaeed and Adel E. EL-Tarras. Iron supplementation at high altitude causes oxidative injury and inflammation in lung tissues of rats. *Toxicology and Applied Pharmacology*, **2014 Jan 1**;274(1):1-6. [Link](#)
 - 22- El-Shaimaa A. Arafa, Ahmed H. Abdelazeem, Hany H. Arab and Hany A. Omar. OSU-CG5, a Novel Energy Restriction Mimetic Agent Inhibits Colorectal Cancer Cells. *Acta Pharmacologica Sinica*, **2014 Mar**; 35(3):394-400. [Link](#)
 - 23- Samir A. Salama, Hany H. Arab, Hany A. Omar and Robert M. Snapka. Nicotine mediates hypochlorous Acid-induced nuclear protein damage in Mammalian cells. *Inflammation*, **2014 Jun**;37(3):785-92. [Link](#)
 - 24- Hany A. Omar, El-Shaimaa A. Arafa, Samir A. Salama and Jing-Ru Weng. OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF- κ B and MAPK signaling pathways. *Toxicology and Applied Pharmacology*, **2013 Nov 1**;272(3):616-24. [Link](#)
 - 25- Khaled R. A. Abdellatif a, Amany Belal, Hany A. Omar. Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues. *Bioorganic & Medicinal Chemistry Letters*, **2013 Sep 1**;23(17):4960-4963 [Link](#)
 - 26- Mohamed A. Abdelgawad, Amany Belal, Hany A. Omar, Lamees Hegazy and Mostafa E. Rateb. Synthesis, Anti-Breast Cancer Activity and Molecular Modeling of Some Benzothiazole and Benzoxazole Derivatives. *Archiv der Pharmazie Chemistry in Life Sci.* **2013**, 346(7), 534–541. [Link](#)
 - 27- Hany A. Omar, Samir A. Salama, El-Shaimaa A. Arafa and Jing-Ru Weng. Antitumor Effects of Energy Restriction-Mimetic Agents: Thiazolidinediones. *Biological Chemistry*, **2013**; 394(7): 865–870. [Link](#)
 - 28- Ahmed O.H. El-Nezhawy, Ayman R. Bioumy, Fatma S. Hassan, Ayman K. Ismaiel and Hany A. Omar. Design, synthesis and pharmacological evaluation of omeprazole-like agents with anti-inflammatory activity. *Bioorganic & Medicinal Chemistry*, **2013 Apr 1**;21(7):1661-1670. [Link](#)
 - 29- Hany A. Omar, Lisa Berman-Booty and Weng JR. Energy restriction: stepping stones towards cancer therapy. *Future Oncology*, **2012 Dec**;8(12):1503-1506. [Link](#)
 - 30- Hany A. Omar, Yihui Ma, Jui-Hsiang Hung, Chih-Chien Chou, Lisa D. Berman-Booty, Dasheng Wang, Takayuki Kogure, Tushar Patel, Natarajan Muthusamy, John C. Byrd, Samuel K. Kulp and

Ching-Shih Chen. Antitumor Effects of OSU-2S, a Non-immunosuppressive Analogue of FTY720, in Hepatocellular Carcinoma. *Hepatology*, 2011 Jun;53(6):1943-58. [Link](#)

- 31- Hany A. Omar, Lisa Berman-Booty, Samuel K. Kulp, and Ching-Shih Chen. Energy Restriction as an Antitumor Target. *Future Oncology*, 2010 Nov; 6(11), 1675–1679. [Link](#)
- 32- Jing-Ru Weng, Hany A. Omar, Samuel K. Kulp, and Ching-Shih Chen. Pharmacological Exploitation of Indole-3-Carbinol to Develop Potent Antitumor Agents. *Mini-Reviews in Medicinal Chemistry*, 2010 May;10(5):398-404. [Link](#)
- 33- Li-Yuan Bai, Hany A. Omar, Chang-Fang Chiu, Zeng-Pang Chi, Jing-Ru Weng. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. *Cancer Chemotherapy and Pharmacology*, 2010 Aug;68(2):489-96. [Link](#)
- 34- Jing-Ru Weng, Li-Yuan Bai, Hany A. Omar, Aaron Sargeant , Ching-Tung Yeh, Yuan-Yin Chen, Ming-Hsui Tsai, Chang-Fang Chiu. A novel indole-3-carbinol derivative inhibits growth of human oral squamous cell carcinoma in vitro. *Oral Oncology*, 2010 Oct; 46(10): 748-754. [Link](#)
- 35- Jing-Ru Weng, Chen-Hsun Tsai, Hany A. Omar, Aaron M. Sargeant, Dasheng Wang, Samuel K. Kulp, Charles L. Shapiro, and Ching-Shih Chen. OSU-A9, a Potent Indole-3-Carbinol Derivative, Suppresses Breast Tumor Growth by Targeting the Akt-NF- κ B Pathway and Stress Response Signaling. *Carcinogenesis*, 2009 Oct;30(10):1702-9. [Link](#)
- 36- Hany A. Omar, Aaron M. Sargeant, Jing-Ru Weng, Dasheng Wang, Samuel K. Kulp, Tushar Patel, and Ching-Shih Chen. Targeting of the Akt-NF- κ B Signaling Network by OSU-A9, a Novel Indole-3-Carbinol Derivative, in a Mouse Model of Hepatocellular Carcinoma. *Molecular Pharmacology*, 2009 Nov;76(5):957-68. [Link](#)

II. SCIENTIFIC ABSTRACTS AND POSTER PRESENTATIONS:

- 1- Jing-Ru Weng, Chen-Hsun Tsai, Hany A. Omar, Aaron Sargeant, Dasheng Wang, Samuel K. Kulp and Ching-Shih Chen. A Potent Indole-3-Carbinol-Derived Antitumor Agent with Pleiotropic Effects on Multiple Signaling Pathways. 1st NCI Translational Science Meeting, Washington, D.C., Apr 29, 2008
- 2- Aaron M. Sargeant, , Chen-Hsun Tsai, Yeater AK, Samuel K. Kulp, Rengel RC, Hany A. Omar, Dasheng Wang, and Ching-Shih Chen. Preclinical Investigation of Novel Indole-3-Carbinol Analogs for prevention and treatment of prostate cancer. The OSU 11th Annual Comprehensive Cancer Center Scientific Meeting, Columbus, Ohio, February 2009.
- 3- Hany A. Omar, Aaron M. Sargeant, Dasheng Wang, Jing-Ru Weng, Samuel K. Kulp, Tushar Patel, and Ching-Shih Chen. OSU-A9, a Novel Indole-3-Carbinol Derivative, in a Murine Model of Hepatocellular Carcinoma. The OSU 11th Annual Comprehensive Cancer Center Scientific Meeting, Columbus, Ohio, February 2009.
- 4- Hany A. Omar, Aaron M. Sargeant, Dasheng Wang, Jing-Ru Weng, Samuel K. Kulp, Tushar Patel, and Ching-Shih Chen. Efficacy of OSU-A9, a Novel Indole-3-Carbinol Derivative, in a Murine Model of Hepatocellular Carcinoma. American Association for Cancer Research 100th Annual Meeting, Denver, Colorado, April, 2009.
Cancer Res May 1, 2009 69; 1826

- 5- **Hany A. Omar**, Aaron M. Sargeant, Dasheng Wang, Jing-Ru Weng, Samuel K. Kulp, Tushar Patel, and Ching-Shih Chen. OSU-A9, a Novel Indole-3-Carbinol Derivative, in a Murine Model of Hepatocellular Carcinoma. OSU Molecular Life Sciences Interdisciplinary Graduate Programs Symposium, Columbus, Ohio, May, **2009**.
- 6- Yihui Ma, Takayuki Kogure, **Hany A. Omar**, Jui-Hsiang Hung, Yen-Shen Lu, Samuel K. Kulp, Tushar Patel, and Ching-Shih Chen. FTY2S, a novel sphingosine-1-phosphate receptor-inactive derivative of FTY720, exhibits high potency in suppressing hepatocellular carcinoma cell growth. The OSU 12th Annual Comprehensive Cancer Center Scientific Meeting, Columbus, Ohio, February 19, **2010**.
- 7- **Hany A. Omar**, Aaron Sargeant, Yu-Chen Ho, Chih-Chien Chou, Jing-Ru Weng, Samuel K. Kulp, and Ching-Shih Chen. OSU-A9M, a novel OSU-A9 derivative with higher antitumor potency through increased oxidative stress induction. The OSU 12th Annual Comprehensive Cancer Center Scientific Meeting, Columbus, Ohio, February 19, **2010**.
- 8- **Hany A. Omar**, Ma Y, Kogure T, Hung JH, Lu YS, Kulp SK, Patel T, and Chen CS. Activation of PKC δ mediates the anticancer effect of the FTY720-derivative, (S)FTY-2, in Hepatocellular Carcinoma. Molecular Life Sciences Interdisciplinary Graduate Programs Symposium. Columbus, Ohio, May 20, **2010**.
- 9- Chih-Chien Chou, **Hany A. Omar**, Aaron Sargeant, Yu-Chen Ho, Jing-Ru Weng, Samuel K. Kulp, and Ching-Shih Chen. OSU-A9M, a novel OSU-A9 derivative with higher antitumor potency through increased oxidative stress induction. College of Pharmacy Research Day and Symposium Columbus, Ohio, May 25, **2010**.
- 10- **Hany A. Omar**, Yihui Ma, Takayuki Kogure, Jui-Hsiang Hung, Yen-Shen Lu, Samuel K. Kulp, Tushar Patel, and Ching-Shih Chen. Antitumor Effects of a Non-immunosuppressive Analogue of FTY720 (Fingolimod), OSU-2S, in Hepatocellular Carcinoma. College of Pharmacy Research Day and Symposium Columbus, Ohio, May 25, **2010**.
- 11- P Neviani, JG Harb, JJ Oaks, C Walker, R Santhanam, C Paisie, A Eiring, B Zhang, B Perazzona, **HA Omar**, CM Marcucci, TL Holyoake, S Volinia, JE. Cortes, MA. Caligiuri, C Huettner, R Bittman, CS Chen, RB Arlinghaus, P Hokland, DC Roy, R Bhatia and D Perrotti. BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph⁺ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment. The 52nd American Society of Hematology (ASH) Annual Meeting and Exposition, Orlando, Florida, USA December 4-7, **2010**.
- 12- **Hany A. Omar**, El-Shaimaa A. Arafa, Jing-Ru Weng. Sensitization of Hepatocellular Carcinoma Cells to TRAIL by a Novel AKt/NF-kB Signaling Inhibitor. AACR Special Conference -Molecularly Targeted Therapies: Mechanisms of Resistance. The Westin San Diego, in San Diego, CA, USA. Wednesday, May 9, to Saturday, May 12, **2012**
Clin Cancer Res May 15, 2012 18; B48 doi: 10.1158/1078-0432.MECHRES-B48
- 13- Samir A. Salama, **Hany A. Omar**, Ibrahim A. Maghrabi, Mohammed S. AlSaeed, Adel E. EL-Tarras. Iron supplementation at high altitude induces inflammation and oxidative injury to lung tissues in rats. Experimental Biology. San Diego Convention Center, in San Diego, CA, USA. April, 26-30, **2014**
The FASEB Journal, April 2014, vol. 28 no. 1 Supplement 708.7
- 14- Hany H. Arab, Samir A. Salama, Ahmed H. Eid, **Hany A. Omar**, El-Shaimaa A. Arafa, Ibrahim A. Maghrabi. Camel's milk ameliorates tri-nitrobenzenesulfonic acid-induced colitis in rats via

downregulation of inflammatory cytokines and oxidative stress. Experimental Biology. San Diego Convention Center, in San Diego, California, USA. April, 26-30, **2014**

The FASEB Journal, April 2014, vol. 28 no. 1 Supplement 134.6

- 15- Mai A. Elhemely, **Hany A. Omar**, Afaf A. Ain-Shoka, Hekma A. Abd El-Latif, Amira M. Abo-youssef, Gamal A. El Sherbiny. Rosuvastatin and ellagic acid protect against isoproterenol-induced myocardial infarction in hyperlipidemic rats. The 8th Dubai International Conference for Medical Sciences Dubai, United Arab Emirates 16-17 December, **2014**.
- 16- Samir A. Zaahkoug, Serag Eldin I. Elbehairi, Aly F. El-Sayed, Sayed Bakry, Alaa Khedr, **Hany A. Omar**, and Ahmed M. Al-Abd, Activity and avascular penetration of FTY720 (fingolimod) and its non-immune suppressant analogue (OSU-2S) within three-dimensional tissue culture model of colorectal cancer. AACR Annual Meeting 2015 in Philadelphia, Pennsylvania, USA. April 18-22, **2015**.
Cancer Res August 1, 2015 75; 4505 doi: 10.1158/1538-7445.AM2015-4505
- 17- **Hany A. Omar**. Energy restriction synergizes doxorubicin activity via targeting breast cancer stem cells. 5th World Congress on Cell & Stem Cell Research. Chicago - North Shore, USA. March 23-25, **2015** [Link](#)
J Cell Sci Ther 2015, 6:2 doi:10.4172/2157-7013.S1.032
- 18- **Hany A. Omar**. Tackling Liver Cancer Cells Survival by OSU-2S/Sorafenib Combination. 7th International Conference on Drug Discovery and Therapy. Sharjah – United Arab Emirates. February 15th-18th **2016** [Link](#)
- 19- Nour Y. Raei, Alaa Eddine Khababa and **Hany A. Omar**. Can oxytocin treat autism? Dubai International Pharmaceuticals and Technologies (DUPHAT) 15-17 March, **2016**.
- 20- Reham Yesnar, Nourhan Yahya and **Hany A. Omar**. Nerve Growth Factor as a Novel Therapeutic Approach for Diverse Clinical Disorders Dubai International Pharmaceuticals and Technologies (DUPHAT) 15-17 March, **2016**.
- 21- **Hany A. Omar**; Mai F. Tolba; Jui-Hsiang Hung; Taleb H. AlTel. Novel approach for Targeting Hepatocellular Carcinoma Cell Survival: OSU-2S/Sorafenib Combination. AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer. Miami, Florida, USA. May 16-19, **2016**
- 22- Dana M. Zaher, Srinivasulu Vunnam, Fatema Hersi, **Hany A. Omar**, Taleb H. Al-Tal. OSU-2S Congeners: Anti-tumor effect of novel and enantiomerically pure pyrrolidine-2-carboxamide derivatives in hepatocellular carcinoma. The 9th Dubai International Conference for Medical Sciences, Dubai, UAE 14-16 December **2016**.
- 23- **Hany A. Omar**. Mai F. Tolba, Jui-Hsiang Hung, Taleb H. AlTel. Mechanistic insights into the significance of sorafenib and OSU-2S combination for the treatment of hepatocellular carcinoma. The 9th Dubai International Conference for Medical Sciences, Dubai, UAE 14-16 December **2016**.
- 24- Basma Ahmed, Nadia Malahfji, Salma Fouz and **Hany A. Omar**. C-pulse Heart Assist System. Dubai International Pharmaceuticals and Technologies (DUPHAT) 7-9, March, **2017**.

- 25- Mai F. Tolba and **Hany A. Omar**; Insights into the anti-prostate cancer activity of pterostilbene. AACR Annual Meeting 2017 in Washington Convention Center Washington, D.C., USA. April 1 - 5, 2017
Cancer Res <https://doi.org/10.1158/1538-7445.Transcontrol16-B45>
- 26- **Hany A. Omar**; Mai F. Tolba; Jui-Hsiang Hung; Taleb H. AlTel. Talking liver cancer by a novel combination between OSU-2S and sorafenib. Experimental Biology Chicago, IL, USA, April 22 – 26, 2017
The FASEB Journal, April 2017, 31 (1 Supplement), 671.1-671.1

INVITED SPEAKER

- 1- Gastrointestinal Cancers 2010: A Multidisciplinary Approach to Prevention, Diagnosis and Treatment. Hosted by Dr. Tanios Bekaii-Saab, medical director of gastrointestinal oncology and assistant professor, division of medical oncology, The Ohio State University. Title: OSU-2S, a novel sphingosine-1-phosphate receptor-inactive derivative of FTY720, exhibits high potency in suppressing hepatocellular carcinoma cell growth. Columbus, OH, USA October 8, 2010.
- 2- The Leukemia & Lymphoma Society at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) hosted by Dr. John Byrd, associate director for translational research at OSUCCC-James, is principal investigator for the SCOR grant. Title: Developing experimental therapeutics for the treatment of adult leukemia. Columbus, OH, USA April 6, 2010.
- 3- Recent Advances in Chemistry and Biology of Natural Products 2014: Title: Natural Products as a Scaffold for Novel Small-molecule Targeted Anticancer Agents. College of Sciences Beni-Suef University, Egypt, August 3-4, 2014
- 4- 5th World Congress on Cell & Stem Cell Research 2015: Title: Energy Restriction Synergizes Doxorubicin Activity via Targeting Breast Cancer Stem Cells. March 23-25, 2015 Chicago, Illinois, USA
- 5- 7th International Conference on Drug Discovery and Therapy. Tackling Liver Cancer Cells Survival by OSU-2S/Sorafenib Combination. Sharjah – United Arab Emirates. February 15th-18th 2016 [Link](#)

Master & Ph.D Thesis Supervision

Ph.D Candidate: Amany Abd-Elkhalek A. Azouz.

Title: *“Novel strategy for cytoprotection of transplanted kidneys”*. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Egypt

Master Candidate: Mustafa Ahmed Abdel-Raheim.

Title: *“Pharmacological study of the possible interactions between antidiabetic drugs and some angiotensin inhibitors in streptozotocin-induced diabetic rats”*. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Egypt

- Master** Candidate: Sayed Mizar Metwally Mizar.
Title: *“Pharmacological study of the possible protective effect of B-blockers and Statins in experimentally-induced liver injury”*. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Egypt
- Master** Candidate: Ahmed Hosni Abdallah.
Title: *“Evaluation of the need to recombinant human erythropoietin in anemia induced by interferon /ribavirin in patients with chronic hepatitis C”*. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Egypt
- Master** Candidate: Dana Hassan Mohamed.
Title: *“Novel OSU-2S-driven cancer chemotherapeutic combinations”*. GRADUATE PROGRAM IN MOLECULAR MEDICINE AND TRANSLATIONAL RESEARCH, College of Pharmacy, University of Sharjah, United Arab Emirates

HONORS, GRANTS & AWARDS

- **2017:** The winner of the Best Innovative Graduate Student Project Award as a supervisor. 11th University of Sharjah Annual Scientific Research Forum. University of Sharjah, (15 May 2017).
- **2017:** The winner of the 4th Best Pharmacy Student Innovative Poster Award as a supervisor. Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT, 7-9 March 2017).
- **2016:** The winner of **273,000 AED** grant as a PI for a research proposal from Al-Jalila Foundation. Title: *“Energy Restriction as a Novel Approach Targeting Cancer Stem Cells Multi-Drug Resistance”*, October 2016
- **2016:** The winner of the University of Sharjah Annual Incentive Award for **Distinguished Faculty Member in Scientific Research** (May, 2016)
- **2016:** The winner of the 2nd Best Pharmacy Student Innovative Poster Award as a supervisor. Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT, 15-17 March 2016).
- **2015:** The winner of **266,000 AED** grant as a Co-PI for a research proposal from Al-Jalila Foundation. Title: *“Targeting Breast and Prostate Cancer: Design and Synthesis of Novel and Privileged polycyclic pyrido[1,2-a]quinolinones, Benzopyranes and Benzoxepines Motifs”*, October 2015
- **2015:** The winner of **150,000 AED** grant as a PI for a research proposal from University of Sharjah. Title: *“Anti-tumor activity of novel metformin and glitazone-derived energy restriction mimetic agents”*, June 2015
- **2015:** The winner of **110,300 AED** grant as a Co-PI for a research proposal from University of Sharjah. Title: *“Prevalence of statin-induced myopathy SLCO 1B1 gene polymorphism in Emirati population”*, June 2015
- **2015:** The winner of Beni-Suef University Encouragement Award for the best research and academic achievement in the last five years, March 2015
- **2014:** The winner of **245,000 AED** grant as a PI for a research proposal from Al-Jalila Foundation. Title: *“OSU-2S Combinatorial Approach, the Next Level in Tackling Cancer Cell Survival”*, August 2014
- **2014:** The winner of **34,000 AED** grant for a student graduation project proposal from Boehringer Ingelheim pharmaceutical company. Title: *“Pre-clinical investigation of novel*

- metformin derivatives as energy restriction mimetic anticancer agents”
- **2014:** [Featured scientific article by Global Medical Discovery](#)
 - **2013:** The winner of 107,000 SR grant as a PI for a research proposal from Taif University Vice-Presidency for Graduate Studies and Research. Title: “The Ability of Novel Energy Restriction Mimetic Agents to target Colorectal Cancer”, March 2013.
 - **2013:** The winner of **86,000 SR** grant as a Co-PI for a research proposal from Taif University Vice-Presidency for Graduate Studies and Research. Title: “Design, Synthesis and Biological Evaluation of Novel Cyclooxygenase-II Inhibitors for the Treatment of Colorectal Cancer”, March 2013.
 - **2012:** The winner of **31,000 LE** Scientific Publication Award for the best published research article with an impact factor of 11.981 (Hepatology, 2011) from Misr El Kheir Foundation
 - **2011:** The winner of 35,000 LE grant for a research proposal from Beni-Suef University Research Centre, Projects Funding and Support Unit, October 2011.
 - **2011:** The best PhD thesis, Beni-Suef University, Egypt, April 2011 [link](#)
 - **2011:** Egyptian Students Association in North America (ESANA) Best Research Award. ESANA-GA annual meeting, January 2011 in Washington, D.C., USA.
 - **2010:** The National Institutes of Health (NIH) travel award to the fifth annual NIH National Graduate Student Research Festival, October 25-26, 2010 in Bethesda, Maryland, USA.
 - **2009:** American Association of Cancer Research (AACR) award to support professional development as an early-career investigator-in-training waiving Associate membership dues for two years, 2010-2011.

PROFESSIONAL MEMBERSHIPS

2010	American Society for Pharmacology and Experimental Therapeutics (ASPET)
2009	American Association for Cancer Research (AACR).
2009	The Egyptian Society of Pharmacology and Experimental Therapeutics.
2009	The American Association of Pharmaceutical Scientists (AAPS)
2008	The Honor Society of Phi Kappa Phi.
2008	American Society Clinical Pharmacology Therapeutics.
2007	American Society for Biochemistry and Molecular Biology.
1998	The General Syndicate of Pharmacists in Egypt.
1998	The Egyptian Association of Pharmacists